BioSpace News Archive

Neon Therapeutics, Inc. announced the acceptance of its Clinical Trial Authorization from the Dutch Health Authority for its personal neoantigen-targeted T cell therapy candidate, NEO-PTC-01.

IRADIMED CORPORATION, a leader in the development of innovative magnetic resonance imaging medical devices and the only known provider of a non-magnetic intravenous infusion pump system and non-magnetic patient vital signs monitoring system that are designed for use during MRI procedures, announced financial results for the three months ended March 31, 2020.

Zentalis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application for ZN-d5, an oral selective inhibitor of B-cell lymphoma 2 initially in development for the treatment of hematologic malignancies.

Starton Therapeutics Inc. announced that it has filed PCT and US Non-Provisional patent applications entitled “Continuous Delivery of Lenalidomide and Other Immunomodulatory Agents” on April 21, 2020.

FDA Submission to Change the Primary Endpoint for Study 106 Phase 3 into an Industry First and Robust Clinical Measure to Evaluate Superiority in CIN

Mesoblast Limited, global leader in cellular medicines for inflammatory diseases, announced a Phase 2/3 randomized, placebo-controlled trial to rigorously confirm whether its allogeneic mesenchymal stem cell therapy remestemcel-L provides a survival benefit in moderate/severe acute respiratory distress syndrome due to COVID-19 has commenced enrollment.

Zimmer Biomet Holdings, Inc. announced that President and CEO Bryan Hanson and Executive Vice President and Chief Financial Officer Suky Upadhyay will be participating in a fireside chat at the Bank of America Merrill Lynch 2020 Health Care Conference on Wednesday, May 13, at 10:20 a.m. Eastern Time.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced that it will release its first quarter 2020 financial results on Thursday, May 7, after the close of the U.S. financial markets..

Provention Bio, Inc., a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, announced that it will report its first quarter 2020 financial results on Thursday, May 7, 2020.

Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, announced dosing of the first patient in a clinical trial to evaluate the administration of ROLONTIS on the same day as chemotherapy.